Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2010-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1535-7163.MCT-10-0213PMID 20937592PMCID PMC4430860
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.

  2012cited by this paper
• A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

  2010cited by this paper
• Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors.

  2009cited by this paper
• Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions.

  2009cited by this paper
• Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth.

  2009cited by this paper
• Broad Antitumor Activity in Breast Cancer Xenografts by Motesanib, a Highly Selective, Oral Inhibitor of Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors

  2009cited by this paper
• Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels.

  2009cited by this paper
• Vascular endothelial growth factor in eye disease.

  2008cited by this paper
• Angiopoietin-2 specific CVX-060 inhibits tumor growth cooperatively with chemotherapy

  2008cited by this paper
• AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adult patients with advanced solid tumors

  2007cited by this paper
• Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy

  2007cited by this paper
• The duality of angiogenesis: implications for therapy of human disease.

  2006cited by this paper
• Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling.

  2006cited by this paper
• Ranibizumab for neovascular age-related macular degeneration.

  2006cited by this paper
• Ranibizumab in neovascular age-related macular degeneration

  2006cited by this paper
• The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review.

  2006cited by this paper
• Angiopoietin-1 promotes lymphatic sprouting and hyperplasia.

  2005cited by this paper
• Angiopoietin 1 causes vessel enlargement, without angiogenic sprouting, during a critical developmental period

  2005cited by this paper
• Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation.

  2005cited by this paper
• The dynamic roles of angiopoietins in tumor angiogenesis.

  2005cited by this paper
• Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy

  2005cited by this paper
• Pegaptanib for neovascular age-related macular degeneration.

  2004cited by this paper
• Effects of gene delivery on collateral development in chronic hypoperfusion: diverse effects of angiopoietin-1 versus vascular endothelial growth factor.

  2004cited by this paper
• Tumorigenesis and Neoplastic Progression Angiopoietin-1 Promotes Tumor Angiogenesis in a Rat Glioma Model

  2004cited by this paper
• Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts.

  2004cited by this paper
• Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2.

  2004cited by this paper
• Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood–retinal barrier

  2004cited by this paper
• Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation

  2003cited by this paper
• Angiopoietin‐2 expression in breast cancer correlates with lymph node invasion and short survival

  2003cited by this paper
• Angiopoietin/Tek Interactions Regulate MMP-9 Expression and Retinal Neovascularization

  2003cited by this paper
• Stabilization of breast cancer xenograft tumour neovasculature by angiopoietin-1

  2002cited by this paper
• Angiopoietin 2 stimulates migration and tube-like structure formation of murine brain capillary endothelial cells through c-Fes and c-Fyn.

  2002cited by this paper
• Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF)

  2002cited by this paper
• Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1.

  2002cited by this paper
• Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice.

  2002cited by this paper
• Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth.

  2002cited by this paper
• Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis.

  2002cited by this paper
• Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases.

  2001cited by this paper
• Inhibition of angiopoietin‐1 expression in tumor cells by an antisense RNA approach inhibited xenograft tumor growth in immunodeficient mice

  2001cited by this paper
• The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer.

  2001cited by this paper
• Expression and function of angiopoietin-1 in breast cancer

  2000cited by this paper
• Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway

  2000cited by this paper
• Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features.

  1999cited by this paper
• VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation

  1999cited by this paper
• Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb.

  1998cited by this paper
• Bacteriophage display and discovery of peptide leads for drug development.

  1997cited by this paper
• Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis.

  1997cited by this paper
• Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis.

  1996cited by this paper
• Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning.

  1996cited by this paper
• A simple technique for preservation of fixation-sensitive antigens in paraffin-embedded tissues.

  1994cited by this paper
• Anticancer strategies involving the vasculature: vascular targeting and the inhibition of angiogenesis.

  1992cited by this paper

• A Highly Active Angiopoietin 1 Mimetic Potentiates Angiogenesis in Mouse Models of Choroidal Neovascularization

  2026cites this paper
• Angiopoietin-2 binds to FGFR2, inhibits FGF-FGFR2 signaling, and delays cutaneous wound healing by inhibiting wound angiogenesis

  2025cites this paper
• Disturbance in cerebral blood microcirculation and hypoxic-ischemic microenvironment are associated with the development of brain metastasis

  2024influential citation
• Evaluating the efficacy and safety of trebananib in treating ovarian cancer and non-ovarian cancer patients: a meta-analysis and systematic review

  2024cites this paper
• Celebrating the 1945 JNCI pioneering contribution to antiangiogenic therapy for cancer.

  2024cites this paper
• Neoadjuvant trebananib plus paclitaxel-based chemotherapy for stage II/III breast cancer in the adaptively randomized I-SPY2 trial - Efficacy and biomarker discovery.

  2023cites this paper
• Exploring the tumor immune microenvironment in ovarian cancer: a way-out to the therapeutic roadmap

  2023cites this paper
• Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers.

  2023cites this paper
• Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade

  2022cites this paper
• MiR-29a Curbs Hepatocellular Carcinoma Incidence via Targeting of HIF-1α and ANGPT2

  2022cites this paper
• Pharmacodynamic and Antitumor Activity of BI 836880, a Dual VEGF and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition

  2022cites this paper
• Pharmacodynamic and Antitumor Activity of BI 836880, a Dual VEGF and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition

  2022cites this paper
• Pharmacodynamic and Antitumor Activity of BI 836880, a Dual VEGF and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition

  2022cites this paper
• Novel Drugs with High Efficacy against Tumor Angiogenesis

  2022cites this paper
• Circulating Angiogenic Markers in Gastroenteropancreatic Neuroendocrine Neoplasms: A Systematic Review

  2022influential citation
• Pharmacodynamic and Antitumor Activity of BI 836880, a Dual Vascular Endothelial Growth Factor and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition

  2022cites this paper
• Abnormal sialylation and fucosylation of saliva glycoproteins: Characteristics of lung cancer-specific biomarkers

  2021cites this paper
• Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer

  2021cites this paper
• Pharmacological Treatment of Advanced, Persistent or Metastatic Endometrial Cancer: State of the Art and Perspectives of Clinical Research for the Special Issue “Diagnosis and Management of Endometrial Cancer”

  2021cites this paper
• Anti-Angiogenesis Maintenance Therapy in Newly Diagnosed and Relapsed Ovarian Cancer: A Meta-analysis of Phase III Randomized Controlled Trials

  2021cites this paper
• Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer

  2021cites this paper
• The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment

  2021cites this paper
• Targeting the SHP2 phosphatase promotes vascular damage and inhibition of tumor growth

  2020cites this paper
• High glucose concentration produces a short-term increase in pERK1/2 and p85 proteins, having a direct angiogenetic effect by an action similar to VEGF

  2020cites this paper
• NRG/RTOG 1122: A phase 2, double‐blinded, placebo‐controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma

  2020cites this paper
• Biology and Therapeutic Targets of Colorectal Serrated Adenocarcinoma; Clues for a Histologically Based Treatment against an Aggressive Tumor

  2020cites this paper
• The αC helix of TIRAP holds therapeutic potential in TLR-mediated autoimmune diseases.

  2020cites this paper
• Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence

  2020cites this paper
• High expression of Tie-2 predicts poor prognosis in primary high grade serous ovarian cancer

  2020cites this paper
• Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2‐Positive Locally Recurrent or Metastatic Breast Cancer

  2019cites this paper
• Anti-angiogenic Targets: Angiopoietin and Angiopoietin Receptors

  2019cites this paper
• Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF

  2019cites this paper
• Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma

  2019cites this paper
• DLC1 deficiency and YAP signaling drive endothelial cell contact inhibition of growth and tumorigenesis

  2019cites this paper
• New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma

  2019cites this paper
• The Role of the VEGF Signaling Pathway in Tumor Angiogenesis

  2019cites this paper
• Linear and Rationally Designed Stapled Peptides Abrogate TLR4 Pathway and Relieve Inflammatory Symptoms in Rheumatoid Arthritis Rat Model.

  2019cites this paper
• Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication

  2019cites this paper
• Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.

  2019cites this paper
• An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting TKI-based therapy

  2019cites this paper
• Anti-angiogenic Targets: Angiopoietin and Angiopoietin-Receptors

  2018cites this paper
• [Local injection of angiopoietin 2 promotes angiogenesis in tissue engineered bone and repair of bone defect with autophagy induction in vivo].

  2018cites this paper
• Synthesis and Biological Evaluation of Chalcone Scaffolds as Potential Antiangiogenic Agents.

  2018cites this paper
• T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection

  2018cites this paper
• Disrupting Tumor Angiogenesis and "the Hunger Games" for Breast Cancer.

  2017cites this paper
• The role of EGFR double minutes in modulating the response of malignant gliomas to radiotherapy

  2017cites this paper
• Tumor angiogenesis and vascular normalization: alternative therapeutic targets

  2017cites this paper
• Cervical cancer cell–derived angiopoietins promote tumor progression

  2017cites this paper
• Current and Emerging Therapies for the Management of Diabetic Retinopathy

  2017cites this paper
• ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.

  2017cites this paper
• Therapeutic targeting of the angiopoietin–TIE pathway

  2017cites this paper
• A Pharmacokinetic and Safety Study of Trebananib, an Fc‐Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction

  2017cites this paper
• Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?

  2017cites this paper
• Overcoming Resistance to Antiangiogenic Therapies

  2017influential citation
• Translational Research in Breast Cancer

  2017influential citation
• Current trend in translational research for treatment of ovarian cancer

  2016cites this paper
• Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer

  2016cites this paper
• Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference.

  2016cites this paper
• Angiopoietin–Tie signalling in the cardiovascular and lymphatic systems

  2016cites this paper
• Angiopoietins Modulate Survival, Migration, and the Components of the Ang-Tie2 Pathway of Chronic Lymphocytic Leukaemia (CLL) Cells In Vitro

  2016cites this paper
• A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors

  2016cites this paper
• Novel anti-angiogenic therapeutic strategies in colorectal cancer

  2016cites this paper
• Emerging Immunotargets in Bladder Cancer.

  2016cites this paper
• Dynamics of the cerebral microvasculature during the course of memory consolidation in the rat : physiological and altered conditions induced by hypertension and hypergravity

  2016cites this paper
• A Phase 1, Open–label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma

  2016cites this paper
• Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack

  2015cites this paper
• New ways to successfully target tumor vasculature in ovarian cancer

  2015cites this paper
• The Angiopoietin—Tie System: Common Signaling Pathways for Angiogenesis, Cancer, and Inflammation

  2015cites this paper
• Landscape and Targeting of the Angpt-Tie System in Current Anticancer Therapy

  2015cites this paper
• Targeting FPR1 and CXCR4 in cancer and the contribution of the tumor microenvironment

  2015cites this paper
• Development of Resistance to Targeted Therapy: Preclinical Findings and Clinical Relevance

  2015cites this paper
• Pharmacokinetic drug–drug interaction assessment of peptibody trebananib in combination with chemotherapies

  2015cites this paper
• Antiangiogenic agents in gynecological cancer: State of art and perspectives of clinical research.

  2015cites this paper
• Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma

  2015cites this paper
• Photoacoustic Tomography Detects Early Vessel Regression and Normalization During Ovarian Tumor Response to the Antiangiogenic Therapy Trebananib

  2015cites this paper
• Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma

  2015cites this paper
• Vasculotide reduces endothelial permeability and tumor cell extravasation in the absence of binding to or agonistic activation of Tie2

  2015cites this paper
• Emerging antibody-based therapeutic strategies for bladder cancer: A systematic review.

  2015cites this paper
• A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial.

  2015cites this paper
• The pathogenic role of angiogenesis in rheumatoid arthritis

  2015cites this paper
• Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.

  2015cites this paper
• A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia.

  2015cites this paper
• University of Groningen Targeting FPR 1 and CXCR 4 in cancer and the contribution of the tumor microenvironment

  2015cites this paper
• Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors

  2015cites this paper
• Targeting angiogenic genes as a therapeutic approach for hepatocellular carcinoma.

  2015cites this paper
• Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386).

  2015cites this paper
• Role of nerve growth factor and its TRKA receptor in normal ovarian and epithelial ovarian cancer angiogenesis

  2014cites this paper
• Recruitment of bone marrow derived cells during anti-angiogenic therapy in GBM: the potential of combination strategies.

  2014cites this paper
• A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery.

  2014cites this paper
• A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.

  2014cites this paper
• A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma.

  2014cites this paper
• Antagonism of Ang-Tie2 and Dll4-Notch signaling has opposing effects on tumor endothelial cell proliferation, evidenced by a new flow cytometry method

  2014cites this paper
• The Role of Angiopoietins as Potential Therapeutic Targets in Renal Cell Carcinoma

  2014cites this paper
• Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer

  2014cites this paper
• Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.

  2014cites this paper
• Angiogenesis and antiangiogenic agents in cervical cancer

  2014cites this paper
• A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours

  2014cites this paper
• Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer

  2014cites this paper
• Pharmacokinetics of Peptide-Fc fusion proteins.

  2014cites this paper
• Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy.

  2013cites this paper